

1 **Article Summary Line:** Transmission of SARS-CoV-2 between people and their pets is
2 common, but can be mitigated by measures to reduce human-animal contact.

3 **Running Title:** SARS-CoV-2 transmission between people and pets

4 **Keywords:** SARS-CoV-2; COVID-19; zoonoses; One Health; anthroozoonoses; household
5 transmission

6 **Word count:** 146 (abstract); 3,499 (text)

7

8 **Household transmission of SARS-CoV-2 from humans to pets in Washington and Idaho:**
9 **burden and risk factors**

10 **Authors:** Julianne Meisner, BVM&S MS^{a*}; Timothy V. Baszler, DVM PhD^{b,c}, Kathryn H.
11 Kuehl, DVM^d, Vickie Ramirez, MA^a, Anna Baines, DVM^a, Lauren A. Frisbie, MPH^e, Eric T.
12 Lofgren, PhD^c, David M. DeAvila MS^b, Rebecca M. Wolking BS^b, Dan S. Bradway BS^{b,c},
13 Hannah Wilson BS^b, Beth Lipton DVM^f, Vance Kawakami DVM^f, Peter M. Rabinowitz, MD
14 MPH^a

15 **Affiliations:**

16 ^aUniversity of Washington, Seattle, WA, USA

17 ^bWashington Animal Disease Diagnostic Laboratory, Washington State University, Pullman,
18 WA, USA

19 ^cPaul G. Allen School for Global Health, Washington State University, Pullman, WA, USA

20 ^dDepartment of Veterinary Clinical Sciences, Washington State University, Pullman, WA, USA

21 ^eWashington State Department of Health, Tumwater, WA, USA

22 ^fPublic Health – Seattle & King County, Seattle, WA, USA

23

24 **Abstract**

25 SARS-CoV-2 is believed to have emerged from an animal reservoir; however, the frequency of
26 and risk factors for inter-species transmission remain unclear. We carried out a community-based
27 study of pets in households with one or more confirmed SARS-CoV-2 infection in humans.

28 Among 119 dogs and 57 cats with completed surveys, clinical signs consistent with SARS-CoV-
29 2 were reported in 20 dogs (21%) and 19 cats (39%). Out of 81 dogs and 32 cats sampled for
30 testing, 40% of dogs and 43% of cats were seropositive, and 5% of dogs and 8% of cats were
31 PCR positive; this discordance may be due to delays in sampling. Respondents commonly
32 reported close human-animal contact and willingness to take measures to prevent transmission to
33 their pets. Reported preventative measures showed a slightly protective trend for both illness
34 and seropositivity in pets, while sharing of beds and bowls had slight harmful effects.

35

36 **Background**

37 Coronaviruses infect multiple mammalian species, and SARS-CoV-2 virus, the
38 etiological agent of COVID-19 infection, likely jumped to humans from a mammalian source
39 [1]. While currently the virus is spreading person to person, the ACE2 receptor involved in
40 SARS-CoV-2 transmission is present in multiple species and there are numerous reports of
41 infections in pets [2–4]. Currently, 110 domestic cats and 95 domestic dogs in the USA have
42 been reported by USDA-APHIS to have SARS-CoV-2 infection [5]. Workplace transmission of
43 SARS-CoV-2 between humans and animals has also been documented, including in zoos (felids
44 and non-human primates) and on mink farms [6,7]. This is consistent with previous reports of
45 SARS-CoV-1 infecting cats and ferrets, and laboratory studies demonstrating experimental
46 SARS-CoV-2 infection of non-human primates, ferrets, hamsters, and rabbits [8]. Less is known,
47 however, about the frequency of and risk factors for SARS-CoV-2 transmission between humans
48 and companion animals in a household setting. Furthermore, the natural history of SARS-CoV-2
49 infection in pets is poorly understood.

50 Given the close contact many people have with their pets and the intimate nature of their
51 shared environment, exacerbated during periods of human quarantine or isolation, it is important
52 to better understand the role of companion animals in community infection patterns, including
53 contribution to virus evolution and emergence of novel strains. In light of evidence from mink
54 farms that animal-origin variants may contain spike mutations and other changes that could
55 affect clinical features of infection [9,10], recent evidence suggesting mouse origins of the
56 omicron variant [11], and Hong Kong’s recent decision to cull 2,000 hamsters after a pet shop
57 worker was infected with the delta variant [12], ongoing monitoring of SARS-CoV-2

58 transmission between humans and animals in household and other human-animal contact settings
59 remains critical.

60 We report our findings from the COVID-19 and Pets Study (CAPS), an ongoing cross-
61 sectional community-based study of pets in households of persons with documented COVID-19
62 infection. The goal of the study is to describe the frequency of transmission between humans and
63 animals within a household, and to determine human, animal, and environmental risk factors for
64 that transmission, in a One Health framework.

65 **Methods**

66 The COHERE [13] and STROBE [14] statements were used to guide reporting of the
67 findings and the preparation of this manuscript.

68 Study population

69 We defined a household as one or more persons ages 18 or older, co-housing with at least
70 one pet that does not live solely outdoors. Pets were defined as dogs, cats, ferrets, and hamsters
71 based on prior research documenting experimental COVID-19 infection in these species [15,16].

72 We conducted this study in King, Snohomish, Yakima, Whitman, Pierce, Spokane, and
73 Benton counties in Washington, and Latah County in Idaho. This paper reports on sampling
74 conducted from April 2020 to September 2021.

75 Study design

76 CAPS is a cross-sectional study with individual- and household-level data collection.
77 Study participation involved two components, detailed below: an online survey followed by
78 animal sampling.

79 Recruitment and eligibility

80 Households were recruited through partnerships with other COVID-19 clinical trials and
81 community studies, social media, word of mouth, community partners, and by contact tracers
82 from Public Health—Seattle & King County during case investigation/contact tracing calls.
83 Individuals were screened for eligibility using the UW Research Electronic Data Capture
84 (REDCap) system [17], a HIPAA-compliant web tool for clinical research, with criteria
85 including county of residence, pet ownership, and one or more household member with
86 confirmed SARS-CoV-2 infection via PCR or antigen testing by a provider or laboratory.
87 Animals with known fearful and/or aggressive behavior were excluded, however, other animals
88 in the corresponding household were eligible.

89 Ethical approvals

90 This study and its protocols received ethical approval from the University of
91 Washington’s Institutional Review Board STUDY00010585) and Office of Animal Welfare
92 (PROTO201600308: 4355-01). Informed consent was obtained via REDCap, or over the phone
93 with the study coordinator, after the nature and possible consequences of study involvement had
94 been explained. Once eligibility was confirmed and consent was obtained, individuals completed
95 the online survey.

96 Survey

97 A comprehensive survey was completed by a household member prior to scheduling of
98 the sampling visit. Surveys were completed online by the study participant using the REDCap
99 interface, or via phone with the study coordinator. Human items included COVID-19 symptom
100 onset, specific symptoms experienced and severity; comorbidities; vaccination status including

101 dates and type; and reported COVID-19-like illness of any other household members, including
102 those who did not have confirmatory testing. Animal items, stratified on individual animal,
103 included veterinary clinical variables, history of illness compatible with SARS-CoV-2 infection,
104 and contact between individual animals and individual members of the household.
105 Environmental items included type and size of home, type of flooring (carpet, wood, etc.), and
106 availability of outdoor space for pets to roam.

107 A second survey was completed verbally at the time of sampling on any changes in the
108 clinical status of human and animal household members since the REDCap survey was
109 completed, including new hospitalizations, symptoms, or COVID-19 diagnoses. Confirmation of
110 SARS-CoV-2 test date and positive result was also performed through review of test results by
111 the sampling team. Self-test results were not accepted.

112 Animal sampling

113 Sampling was performed by a team of two study personnel including at least one
114 veterinarian. In most cases sampling was conducted at the participant's home; however, several
115 animals were tested at veterinary hospitals. No chemical restraint was used, nor muzzles due to
116 biosafety concerns.

117 Species-appropriate restraint was employed using standard techniques to allow for
118 venipuncture and collection of 3 mL of blood into a labeled serum separator tube. Following
119 venipuncture, swab samples were collected from both rostral nares/nasal passage and the caudal
120 oropharynx and then placed into one Primestore Molecular Transport Medium (MTM) tube. A
121 separate fecal swab was collected from the rectum and placed into a separate Primestore MTM

122 tube. All participants received educational information from the field team about measures to
123 mitigate household COVID-19 transmission.

124 Swab and serum samples were transported on ice within 24 hours to the Washington
125 Animal Disease Diagnostic Laboratory (WADDL) for PCR and antibody testing.

126 Testing

127 *SARS-CoV-2 RT-PCR*

128 Respiratory or fecal swabs: RNA extraction and SARS-Cov-2 reverse transcriptase (RT)
129 real-time PCR was performed as described [18]. Following initial viral detection by PCR, three
130 dog samples and one cat sample were submitted to University of Minnesota Genomics Center
131 (Oakdale, MN 55128) for whole genome sequencing (WGS) [19]. A second cat sample was
132 submitted to the USDA National Veterinary Services Laboratories (NVSL) in Ames Iowa for
133 WGS. Mutational analysis was performed using the GISAID EpiFlu Database CoVsurver:
134 Mutation Analysis of hCoV-19 [20,21]. All five sequences were deposited into GISAID, with
135 accession numbers EPI_ISL_7845315, EPI_ISL_7845316, EPI_ISL_7845317,
136 EPI_ISL_7845318, and EPI_ISL_8897004. SARS-CoV-2 lineages were assigned using the
137 Phylogenetic Assignment of Named Global Outbreak LINEages (Pango lineage) tool [22,23].

138 *SARS-CoV-2 Spike Protein Receptor Binding Domain (RBD) ELISA*

139 WADDL developed canine and feline SARS-CoV-2 ELISA assays using recombinant
140 SARS-CoV-2 Spike Receptor Binding Domain protein as antigen (S-RBD). The recombinant
141 RBD was obtained from the UW Center for Emerging and Reemerging Infectious Disease
142 (CERID) laboratory of Dr. Wesley Van Voorhis through an institutional Material Transfer

143 Agreement. WADDL used an in-house standard operating procedure for indirect ELISA of
144 SARS-CoV-2 in 96-well format based on a previous publication in humans [24]. The major
145 components of the assay included: 1) rS-RBD coating of plates as target antigen (2 μ g/ml in
146 Sigma Carbonate-Bicarbonate Buffer); 2) 1:100 dilution of test sera (diluted in ChronBlock
147 ELISA Buffer-Chondrex Inc.); 3) anti dog IgG-HRP as linker (Southern BioTech goat anti-
148 canine IgG) and 4) Sigma (TMB) liquid substrate system to develop OD. Plates were blocked
149 with ChronBlock ELISA buffer per manufacturer's instructions, washing solution consisted of
150 PBS+0.1% Tween 20 (Sigma), and plates were read on a plate reader at 450 nM. Test sera were
151 run in triplicate and utilized at "*test OD*".

152 For the canine RBD ELISA, the negative controls consisted of sera from six pre-COVID
153 dogs, archived at WADDL and tested for canine Adenovirus (CAV), canine Distemper Virus
154 (CDV), canine Coronavirus (CCV), canine Parainfluenza (CPI), and canine Parvovirus (CPV)
155 IgG. All six samples had antibody presence of one or more of the tests performed, however no
156 sera reacted in the SARS-CoV-2 canine RBD ELISA. For the cat RBD ELISA, the negative
157 controls consisted of sera from three pre-COVID cats from WADDL archives, tested for feline
158 Coronavirus (FIP-FeCV) and feline Panleukopenia Virus (FPV)- IgG. Two of the three samples
159 had antibody presence of one or more of the tests performed (including 2 for FIP-FeCV);
160 however, neither reacted in the SARS-CoV-2 feline RBD ELISA. Negative controls were run in
161 triplicate and the mean was utilized as "*negative control OD*." A ratio of *test OD: negative*
162 *control OD* was used to determine the results. The positive cutoff of 2.0 *test OD: negative*
163 *control OD* ratio equated to the mean of negative controls + 3 standard deviations of the mean.

164 SARS-CoV-2 RBD ELISA was repeated three times for all samples, and the final results
165 were tabulated as a mean value obtained from the repeated testing. As no dog or cat in

166 Washington or Idaho had been confirmed to be SARS CoV-2 positive via serology prior to our
167 study, the first antibody positive case for each species and state was sent to the NVSL for
168 confirmation via virus neutralization (VN) assay in keeping with regulatory recommendations.
169 Both canine and feline SARS-CoV-2 RBD ELISA positive samples were confirmed at NVSL by
170 VN.

171 Statistical analyses

172 The primary aim of this study was to estimate the burden of household SARS-CoV-2
173 transmission from humans to their pets. Secondary aims included describing the nature of
174 human-animal contact within households and identifying risk factors for household transmission,
175 including human-animal contact. All analyses were conducted in R [25].

176 *Outcome*

177 Animal infection with SARS-CoV-2 was defined as an animal meeting one or more of
178 the following criteria: (1) SARS CoV-2 RBD ELISA seropositive status, (2) PCR positive status,
179 or (3) illness consistent with SARS-CoV-2 infection, hereafter referred to as “illness,” defined as
180 participant answer of “yes” to the survey question: “Since the time of COVID
181 diagnosis/symptom onset in the household, has this animal had any new issues with difficulty
182 breathing, coughing and/or decreased interest in playing, walking, or eating?” Serostatus was
183 parameterized as ELISA ratio, log-transformed for the sake of interpretability; PCR positive
184 status and illness were parameterized as binary variables.

185 *Regression models*

186 Outcome was defined as an animal case of SARS-CoV-2 (definition above). Separate
187 regression models were fit for each outcome definition.

188 Household-level exposures for animal infection included residence in house versus
189 apartment or condominium (binary), home size in square feet (continuous), and the number of
190 human confirmed SARS-CoV-2 cases (continuous). Animal-level exposures for infection
191 included bedsharing with one or more human household members (binary), sharing bowls with
192 one or more household members (binary), and SARS-CoV-2 positive household members taking
193 precautions to prevent transmission to their pets following diagnosis, including not petting or
194 kissing the animal, staying in a different room, and having someone else feed and walk the
195 animal (binary). We also examined the association between canine seropositivity and illness
196 compatible with SARS-CoV-2 infection in the animal, and between seropositivity and time since
197 the animal was first exposed, defined as two days prior to the first date any household member
198 had symptoms of COVID-19 or tested positive, whichever was earlier.

199 We identified possible confounders *a priori* using a directed acyclic graph (DAG; Figure
200 1). The minimum sufficient adjustment set was defined, using this DAG and DAGitty.net,
201 separately for each exposure [26]. Animal species was explored as an effect modifier using a
202 multiplicative interaction term, and stratified results presented in all cases in which this
203 interaction term reached statistical significance ($p \leq 0.05$).

204 For each exposure of interest we implemented a generalized estimating equation (GEE)
205 approach with an exchangeable working correlation structure, household as the clustering
206 variable, and binomial models with a logit (binary outcomes) or Gaussian (continuous outcomes)

207 link, using the geepack package in R [27]. For regression of ELISA ratio on illness and time
208 since first exposure, we performed linear regression using the glm() function in R.

209 **Results**

210 Recruitment

211 In total, 107 eligible households enrolled and completed the survey. No households
212 currently living as unhoused enrolled. Two households corresponded to a single dog which was
213 moved from the participant's home to a family member's home immediately after the onset of
214 the participant's COVID-19 symptoms, leaving 105 households corresponding to 119 dogs and
215 57 cats available for analyses; no ferrets or hamsters enrolled or were sampled.

216 Sample collection is detailed in Figure 2. In total, 83 households corresponding to 100
217 dogs and 47 cats had a sampling visit conducted. Of these, six dogs and eight cats belonged to
218 households were not sampled due to temperament, leaving 94 dogs and 39 cats with PCR results,
219 while an additional 13 dogs and 9 cats were safe to restrain for swab (PCR) samples but not for
220 serum collection, leaving 81 dogs and 32 cats with serology results.

221 Descriptive statistics

222 Descriptive statistics are presented in Table 1. On average, at least six weeks (dogs) and
223 two weeks (cats) elapsed between the last human COVID-19 diagnosis in the household and
224 animal sampling. Of the 119 dogs and 57 cats with completed surveys, 20.4% (95% CI 12.9%,
225 29.7%) of dogs and 38.8% (95% CI 25.2%, 53.8%) of cats had reported illness. Of the 94 dogs
226 and 39 cats who were PCR tested, 5.3% (95% CI 1.8%, 12%) of dogs and 7.7% (95% CI 1.6%,
227 20.9%) of cats were positive; of the 81 dogs and 32 cats who had serum collected, 40.2% (95%

228 CI 29.6%, 51.7%) of dogs and 40.6% (95% CI 23.7%, 59.4%) of cats were seropositive.
229 Individual animal SARS-CoV-2 RBD ELISA results are shown in Figure 3 (dogs) and Figure 4
230 (cats). SARS-CoV-2 RBD ELISA test OD:negative control OD ratios in seropositive animals
231 ranged from 2.03 – 21.22 in dogs and from 3.01 – 30.35 in cats.

232 Five dog swabs (Cts 26.08 – 37.67) and 3 cats (Cts 27.03 – 39.97) were PCR positive on
233 nasal/oropharyngeal swabs; one of these dogs was also PCR positive from fecal swab (Ct 39.20).
234 Five PCR positive samples (2 cats and 3 dogs) had Cts sufficient for WGS (Ct<30): The earliest
235 cat sample (April 2021) that underwent WGS fell into Pango clade B.1.2. A later dog sample
236 sequenced as Delta sublineage B.1.617.2.103 (AY103), while the other three (2 cat, 1 dog)
237 samples sequenced as Delta sublineage B.1.617.2.25 (AY25). Of the five PCR positive dogs,
238 three were PCR positive prior to being seropositive and two were simultaneously PCR and
239 seropositive.

240 There were 11 households with two or more positive animals, and among multi-pet
241 households with at least one positive pet, mean prevalence (PCR or serology) was 91%. Out of
242 eight total PCR positive cases, all were detected after April 2021, when the first case of the Delta
243 variant was documented in Washington State.

244 Nearly one-third of dogs engaged in activities outside of the household during periods of
245 human isolation or quarantine. Over 50% of both cats and dogs resided in households whose
246 residents reported awareness of CDC guidelines to prevent human-animal transmission of
247 SARS-CoV-2, and 48 (41%) dogs and 17 (30%) cats resided in households which reported
248 taking precautions to prevent such transmission to household pet(s) following diagnosis. No cats
249 and only two dogs resided in a household in which an infected person was hospitalized for

250 COVID-19. Nearly all dogs (83%) and most cats (72%) had access to yards or gardens and were
251 allowed on furniture (86% of dogs and 100% of cats), and the majority were kissed by (75% of
252 dogs and 68% of cats) and shared beds (69% of dogs and 73% of cats) with human household
253 members. Almost all dogs' (91%) and cats' (95%) bowls were washed in the kitchen.

254 Regression models

255 Results of regression models are presented in Table 2 as prevalence odds ratios for the
256 binary outcome of illness, reflecting the cross-sectional design of this study, and as \exp^{β} for the
257 outcome of ELISA ratio, which can be interpreted as the relative change (ratio scale) in ELISA
258 ratio for a one unit change in the exposure. As so few animals were PCR positive, we did not run
259 regression models for this outcome. With the exception of house size, which was adjusted for
260 house type as the minimum sufficient adjustment set was very small for this exposure,
261 confounders were not adjusted for due to concerns regarding overfitting arising from the small
262 sample size. Effect modification by species was found only for house type.

263 Dogs residing in houses on average had a 79% (95% CI 2%, 211%) higher ELISA ratio
264 than dogs residing in apartments or condos, while the inverse association was detected for cats
265 (49% lower mean ELISA ratio, 95% CI 75% lower, 3% higher) and for the outcome of illness in
266 both cats and dogs (48% lower prevalence odds, 95% CI 80% lower, 34% higher); this
267 association reached statistical significance for dogs only. No other effect estimates reached
268 statistical significance; however, there were positive trends across both outcome definitions for
269 bed sharing with humans, sharing bowls, and being indoor only; and a negative effect for
270 precautions taken to prevent SARS-CoV-2 transmission following diagnosis. We also found
271 ELISA ratio was positively associated with illness; however, we did not find evidence of an

272 effect of time since first exposure on ELISA ratio, nor of house square footage on either
273 outcome.

274 **Discussion**

275 We present the results of a cross-sectional, One Health study of SARS-CoV-2
276 transmission between people and their pets. The study results indicate that household
277 transmission of SARS-CoV-2 from humans to animals occurs frequently and infected animals
278 commonly display signs of illness. Notably, in 9 out of 11 households with multiple pets of
279 whom at least one tested positive (PCR or serology), all tested pets were positive. We
280 furthermore show that close human-animal contact is common among people and their pets in
281 this study population, that this contact appears to facilitate SARS-CoV-2 transmission, and that
282 pet owners are familiar with and willing to adopt measures to protect their pets from COVID-19.

283 There are several limitations to our approach. First, several weeks had elapsed from first
284 reported exposure to household sample collection from animals in most households, possibly
285 limiting our ability to detect viral shedding by PCR testing but strengthening our ability to detect
286 seroconversion. Second, while we assume transmission is from humans to pets, the cross-
287 sectional nature of this study precludes certainty regarding the direction of transmission.
288 Nevertheless, as SARS-CoV-2 is transmitted predominantly human-to-human, few cases of
289 SARS-CoV-2 have been documented in dogs and cats, and no cases have been documented to be
290 transmitted from dogs or cats to humans, we believe transmission in this study was exclusively
291 from humans to pets. Third, our study is subject to residual confounding due to inability to adjust
292 for confounders without risking over-fitting. We do not expect unmeasured or unadjusted
293 confounders to exert strong effects other than latent (and therefore difficult to measure and

294 model) constructs, such as socioeconomic status, strength of the human-animal bond, and level
295 of concern about zoonotic disease transmission. Finally, our definition of illness in pets is
296 simple, derived from a single survey item, and vulnerable to misclassification if these clinical
297 signs are due to other etiologies. This survey was created early in the COVID-19 pandemic,
298 although illness in pets is still not well-characterized.

299 We believe respondents misunderstood the question, “Is this animal indoor only vs.
300 indoor/outdoor” as 37% of dogs were reported to be indoor-only, however we believe this
301 variable retains its connection to degree of animal contact despite mismeasurement (i.e., a dog
302 labeled as “indoor only” likely spends more time in an indoor setting with humans than a dog
303 labeled as indoor/outdoor). We do not expect strong measurement error in any of the other
304 variables examined. As no gold-standard for canine anti-SARS-CoV-2 serology exists, validation
305 of our ELISA assay was limited to analytic validation and we could not reliably estimate
306 diagnostic sensitivity of our serological test; full diagnostic validation was not possible due to the
307 absence of sufficient gold-standard positive and negative samples, a limitation arising from the
308 status of SARS-CoV-2 as an emerging pathogen. However, all pre-COVID-19 samples evaluated
309 were negative, indicating specificity approaches 100%, and all samples sent to USDA-NVSL for
310 confirmatory PCR and serology testing had concordant results. While our primary aim—to
311 estimate the burden of human-animal SARS-CoV-2 transmission—was estimated with
312 reasonable precision, due to our small sample size variance was high for effect estimates
313 produced by our regression model. Finally, by nature of our recruitment methods and study
314 population, generalizability of our findings is likely limited to highly-educated, higher-income
315 individuals residing in urban and suburban communities.

316 **Conclusions**

317 These limitations aside, our study contributes important and novel findings to the
318 literature on cross-species transmission of SARS-CoV-2, with relevance to other zoonoses
319 transmitted in a household setting. Furthermore, we collected human, animal, and environmental
320 data, representing a true One Health approach to this critical research question. Finally, our
321 findings indicate households in this population are willing to adopt measures to protect their pets
322 from SARS-CoV-2 infection, and that these measures may be effective, indicating an
323 opportunity to prevent household transmission of zoonoses through health education and policy.

324 **Acknowledgements**

325 Data collection: Jessica Bell, DVM and Raelynn Farnsworth, DVM, Washington State
326 University College of Veterinary Medicine; Katherine Burr, DVM and Gemina Garland Lewis,
327 MS, Center for One Health Research, University of Washington.

328 Survey Review: J. Scott Weese, Ontario Veterinary College, University of Guelph.

329 Recombinant SARS-CoV-2 receptor binding domain source material: Dr. Wes Van Voorhis,
330 Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle,
331 WA, USA [28,29].

332 **Funding:**

333 The project was funded in part with funds from: 1) Department of Health and Human Services,
334 FDA Vet-LIRN Veterinary Diagnostic Laboratory Program grant #5U18FD006180-04, 2)
335 National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department
336 of Health and Human Services, under Contract No.: HHSN272201700059C (WCV) and grant

337 U01 AI151698 (WCV) for the United World Antivirus Research Network (UWARN), and 3)

338 Wild Lives Foundation.

339 **Author Bio**

340 Julianne Meisner is a post-doctoral fellow in Environmental and Occupational Health

341 Sciences at the University of Washington. Her research interests lie at the intersection of human

342 and animal health, and the application of rigorous epidemiologic methods to research at this

343 interface.

344

345 References

- 346 [1] M. Konda, B. Dodda, V.M. Konala, S. Naramala, S. Adapa, Potential Zoonotic Origins of
347 SARS-CoV-2 and Insights for Preventing Future Pandemics Through One Health
348 Approach, *Cureus*. (2020). <https://doi.org/10.7759/cureus.8932>.
- 349 [2] M. Kiros, H. Andualem, T. Kiros, W. Hailemichael, S. Getu, A. Geteneh, D. Alemu, W.E.
350 Abegaz, COVID-19 pandemic: current knowledge about the role of pets and other animals
351 in disease transmission. , *Virologia* 17 (2020) 143.
- 352 [3] A. Csiszar, F. Jakab, T. Valencak, Z. Lanszki, G. Tóth, G. Kemenesi, S. Tarantini, V.
353 Fazekas-Pongor, Z. Ungvari, Companion animals likely do not spread COVID-19 but may
354 get infected themselves, *Geroscience*. 42 (2020) 1229–1236.
- 355 [4] T.S. Salajegheh, D.P. Magalhães, P. Rahimi, F. Shahabinejad, S. Dhakal, M.Y. Singh, A.
356 Shehata, J. Lama, J. Klein, M. Safdar, M. Rahman, Filipiak KJ, A. Rodríguez-Morales, M.
357 Sobur, F. Kabir, B. Vazir, L. Mboera, M. Caporale, M. Islam, J. Amuasi, R. Gharieb, P.
358 Roncada, S. Musaad, B. Tilocca, M. Koohi, A. Taghipour, A. Sait, K. Subbaram, A.
359 Jahandideh, P. Mortazavi, M. Abedini, D. Hokey, U. Hogan, M. Shaheen, A. Elaswad, M.
360 Elhaig, M. Fawzy, Transmission of severe acute respiratory syndrome coronavirus 2
361 (SARS-CoV-2) to animals: an updated review, *J Transl Med*. 18 (2020) 358.
- 362 [5] US Department of Agriculture, Animal and Plant Health Inspection Service,
363 <https://www.aphis.usda.gov/aphis/Dashboards/Tableau/Sars-Dashboard>. (2022).
- 364 [6] R.J. Molenaar, S. Vreman, R.W. Hakze-van der Honing, R. Zwart, J. de Rond, E.
365 Weesendorp, L.A.M. Smit, M. Koopmans, R. Bouwstra, A. Stegeman, W.H.M. van der
366 Poel, Clinical and Pathological Findings in SARS-CoV-2 Disease Outbreaks in Farmed
367 Mink (*Neovison vison*), *Veterinary Pathology*. (2020).
368 <https://doi.org/10.1177/0300985820943535>.
- 369 [7] B.E.E. Martina, B.L. Haagmans, T. Kuiken, R.A.M. Fouchier, G.F. Rimmelzwaan, G.
370 Van Amerongen, J.S.M. Peiris, W. Lim, A.D.M.E. Osterhaus, SARS virus infection of
371 cats and ferrets, *Nature*. (2003). <https://doi.org/10.1038/425915a>.
- 372 [8] American Veterinary Medical Association, SARS-CoV-2 in Animals, (n.d.).
373 [www.avma.org/resources-tools/animal-health-and-welfare/covid-19/sars-cov-2-animals-](http://www.avma.org/resources-tools/animal-health-and-welfare/covid-19/sars-cov-2-animals-including-pets)
374 [including-pets](http://www.avma.org/resources-tools/animal-health-and-welfare/covid-19/sars-cov-2-animals-including-pets).
- 375 [9] P. F, SARS-CoV-2 variants lacking ORF8 occurred in farmed mink and pangolin, *Gene*.
376 784 (2021) 145596. <https://doi.org/10.1016/j.gene.2021.145596>.
- 377 [10] S. Guo, K. Liu, J. Zheng, The Genetic Variant of SARS-CoV-2: Would it matter for
378 Controlling the Devastating Pandemic?, *International Journal of Biological Sciences*.
379 (2021). <https://doi.org/10.7150/ijbs.59137>.
- 380 [11] C. Wei, K. Shan, W. Wang, S. Zhang, Q. Huan, W. Qian, Evidence for a mouse origin of
381 the SARS-CoV-2 Omicron variant, *J Genet Genomics*. 21 (2021) S1673-8527.
- 382 [12] de Guzman, Hong Kong Says Hamsters May Have Infected a Pet Shop Worker With
383 COVID-19. Now They All Must Die, [https://time.com/6139876/hong-kong-hamsters-](https://time.com/6139876/hong-kong-hamsters-covid-19/)
384 [Covid-19/](https://time.com/6139876/hong-kong-hamsters-covid-19/). (2022). <https://time.com/6139876/hong-kong-hamsters-covid-19/> (accessed
385 January 23, 2022).
- 386 [13] M.F. Davis, S.C. Rankin, J.M. Schurer, S. Cole, L. Conti, P. Rabinowitz, G. Gray, L.
387 Kahn, C. Machalaba, J. Mazet, M. Papaioanou, J. Sargeant, A. Thompson, S. Weese, J.
388 Zinnstag, Checklist for One Health Epidemiological Reporting of Evidence (COHERE),
389 *One Health*. (2017). <https://doi.org/10.1016/j.onehlt.2017.07.001>.

- 390 [14] STROBE statement - Checklist of items that should be included in reports of
391 observational studies (© STROBE Initiative), International Journal of Public Health.
392 (2008). <https://doi.org/10.1007/s00038-007-0239-9>.
- 393 [15] M. Imai, K. Iwatsuki-Horimoto, M. Hatta, S. Loeber, P.J. Halfmann, N. Nakajima, T.
394 Watanabe, M. Ujie, K. Takahashi, M. Ito, S. Yamada, S. Fan, S. Chiba, M. Kuroda, L.
395 Guan, K. Takada, T. Armbrust, A. Balogh, Y. Furusawa, M. Okuda, H. Ueki, A.
396 Yasuhara, Y. Sakai-Tagawa, T.J.S. Lopes, M. Kiso, S. Yamayoshi, N. Kinoshita, N.
397 Ohmagari, S.I. Hattori, M. Takeda, H. Mitsuya, F. Krammer, T. Suzuki, Y. Kawaoka,
398 Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure
399 development, Proceedings of the National Academy of Sciences of the United States of
400 America. (2020). <https://doi.org/10.1073/pnas.2009799117>.
- 401 [16] J. Shi, Z. Wen, G. Zhong, H. Yang, C. Wang, B. Huang, R. Liu, X. He, L. Shuai, Z. Sun,
402 Y. Zhao, P. Liu, L. Liang, P. Cui, J. Wang, X. Zhang, Y. Guan, W. Tan, G. Wu, H. Chen,
403 Z. Bu, Z. Bu, Susceptibility of ferrets, cats, dogs, and other domesticated animals to
404 SARS-coronavirus 2, Science. (2020). <https://doi.org/10.1126/science.abb7015>.
- 405 [17] P.A. Harris, R. Taylor, B.L. Minor, V. Elliott, M. Fernandez, L. O’Neal, L. McLeod, G.
406 Delacqua, F. Delacqua, J. Kirby, S.N. Duda, The REDCap consortium: Building an
407 international community of software platform partners, Journal of Biomedical Informatics.
408 (2019). <https://doi.org/10.1016/j.jbi.2019.103208>.
- 409 [18] C. Eckstrand, T. Baldwin, K. Rood, M. Clayton, J. Lott, R. Wolking, D. Bradway, T.
410 Baszler, An outbreak of SARS-CoV-2 with high mortality in mink (*Neovison vison*) on
411 multiple Utah farms, PLoS Pathog. 17 (2021) e1009952.
- 412 [19] J. Plitnick, S. Griesemer, E. Lasek-Nesselquist, N. Singh, D. Lamson, K. St George,
413 Whole-Genome Sequencing of SARS-CoV-2: Assessment of the Ion Torrent AmpliSeq
414 Panel and Comparison with the Illumina MiSeq ARTIC Protocol, J Clin Microbiol. 59
415 (2021) e006492.
- 416 [20] GISAIID, CoVsurver: Mutation Analysis of hCoV-19, [https://www.gisaid.org/epiflu-](https://www.gisaid.org/epiflu-applications/covsurver-mutations-app)
417 [Applications/Covsurver-Mutations-App](https://www.gisaid.org/epiflu-applications/covsurver-mutations-app). (2022).
- 418 [21] S. Khare, C. Gurry, L. Freitas, M. Schultz, G. Bach, A. Diallo, N. Akite, J. Ho, R. Lee, W.
419 Yeo, Curation Team GC, S. Maurer-Stroh, GISAIID’s Role in Pandemic Response, China
420 CDC Wkly. 3 (2021) 1049–1051.
- 421 [22] A. Rambaut, E. Holmes, Á. O’Toole, V. Hill, J. McCrone, C. Ruis, L. du Plessis, O.
422 Pybus, A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic
423 epidemiology., Nat Microbiol. 5 (2020) 1403–1407.
- 424 [23] Á. O’Toole, V. Hill, J. McCrone, E. Scher, A. Rambaut, Pangolin COVID-19 Lineage
425 Assigner, <https://pangolin.cog-uk.io/>. (2022).
- 426 [24] I. Phan, S. Subramanian, D. Kim, M. Murphy, D. Pettie, L. Carter, I. Anishchenk, L.
427 Barrett, J. Craig, L. Tillery, R. Shek, W. Harrington, D. Koelle, A. Wald, D. Veessler, N.
428 King, J. Boonyaratanakornkit, N. Isoherranen, A. Greninger, K. Jerome, H. Chu, B.
429 Staker, L. Stewart, P. Myler, W. van Voorhis, In silico detection of SARS-CoV-2 specific
430 B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19, Sci Rep.
431 11 (2021) 4290.
- 432 [25] R.F. for S. Computing., R Core Team 2020, R: A Language and Environment for
433 Statistical Computing. (2020).

- 434 [26] J. Textor, B. van der Zander, M.S. Gilthorpe, M. Liškiewicz, G.T. Ellison, Robust causal
435 inference using directed acyclic graphs: The R package “dagitty,” *International Journal of*
436 *Epidemiology*. (2016). <https://doi.org/10.1093/ije/dyw341>.
- 437 [27] S. Højsgaard, U. Halekoh, J. Yan, The R Package geepack for Generalized Estimating
438 Equations *Journal of Statistical Software, CRAN*. (2006).
- 439 [28] A.C. Walls, Y.J. Park, M.A. Tortorici, A. Wall, A.T. McGuire, D. Veessler, Structure,
440 Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein, *Cell*. (2020).
441 <https://doi.org/10.1016/j.cell.2020.02.058>.
- 442 [29] I.Q. Phan, S. Subramanian, D. Kim, M. Murphy, D. Pettie, L. Carter, I. Anishchenko, L.K.
443 Barrett, J. Craig, L. Tillery, R. Shek, W.E. Harrington, D.M. Koelle, A. Wald, D. Veessler,
444 N. King, J. Boonyaratanakornkit, N. Isoherranen, A.L. Greninger, K.R. Jerome, H. Chu,
445 B. Staker, L. Stewart, P.J. Myler, W.C. Van Voorhis, In silico detection of SARS-CoV-2
446 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19,
447 *Scientific Reports*. (2021). <https://doi.org/10.1038/s41598-021-83730-y>.
448
449

450

	n (%)	
	Dogs (N=119)	Cats (N=57)
<i>Animal</i>		
Illness consistent with SARS-CoV-2	20 (20%)	19 (39%)
Seropositive	33 (40%)	13 (41%)
PCR positive	5 (5%)	3 (8%)
ELISA ratio	3.9 (4.93)*	9.88 (12.51)*
Activity ^a during human quarantine	33 (28%)	7 (12%)
Respondent took precautions ^b	48 (41%)	17 (30%)
Age	6.05 (3.86)*	6.40 (4.50)*
Male	66 (56%)	28 (49%)
Respondent aware of CDC guidelines ^c	62 (53%)	29 (53%)
Time from first diagnosis ^d to sampling (days)	51.17 (60.64)*	29.28 (19.17)*
Time from last diagnosis ^d to sampling (days)	43.06 (69.44)*	15.16 (40.93)*
<i>Humans</i>		
Index case age	41.78 (13.24)*	47.91 (14.38)*
Index case male	34 (29%)	14 (25%)
Index case preexisting condition ^e	27 (23%)	18 (32%)
Index case was hospitalized	2 (2%)	0 (0%)
No. SARS-CoV-2 positive household members	1.78 (1.28)*	1.72 (1.13)*

No. household members with COVID-19-like symptoms ^f	0.27 (0.63)*	0.26 (0.55)*
No. household residents	3.43 (1.49)*	3.07 (1.28)*
<i>Environment</i>		
Reside in a house	91 (76%)	51 (89%)
Reside in an apartment or condominium	51 (24%)	6 (11%)
Square footage of housing	1856.32 (932.74)*	1980.88 (1095.15)*
Number of bedrooms	3.24 (1.4)*	3.19 (1.22)*
Number of floors	1.87 (0.82)*	1.84 (0.62)*
Access to outdoor space where pets can roam	99 (83%)	41 (72%)
<i>Human-animal contact</i>		
Bowls used by animals cleaned in the kitchen	108 (91%)	54 (95%)
Humans and animals share bowls	15 (13%)	8 (14%)
Humans wash hands before handling animals	15 (13%)	2 (4%)
Humans wash hands after handling animals	50 (42%)	12 (21%)
Animal bedshares with humans	81 (69%)	41 (73%)
Animal shares a bedroom but not a bed with humans	54 (46%)	19 (34%)
Animal is indoor-only	43 (37%)	35 (61%)
Animal sleeps outdoors	1 (1%)	5 (9%)
Humans pet the animal	117 (100%)	56 (100%)
Humans kiss the animal	88 (75%)	38 (68%)
Animal is allowed on furniture	101 (86%)	56 (100%)

451 **Table 1: Descriptive statistics for 119 dogs and 57 cats corresponding to 105 households.**

452 *mean (standard deviation). ^aActivity defined as going to a veterinary clinic or groomer, being
453 walked off-leash, or visiting an off-leash park, dog park, kennel, or daycare facility. ^bPrecautions
454 to prevent human-animal SARS-CoV-2 transmission following diagnosis: not petting or kissing
455 the animal, staying in a different room, and having someone else feed and walk the animal.
456 ^cGuidelines to prevent human-animal SARS-CoV-2 transmission. ^dFirst diagnosis: earliest
457 known, confirmed SARS-CoV-2 diagnosis in the household; final diagnosis: last known,
458 confirmed SARS-CoV-2 diagnosis in the household. ^ePreexisting conditions: diabetes, kidney
459 disease, heart disease, hypertension, immunosuppression. ^fHousehold members who had
460 COVID-19-like symptoms but did not get tested.

461

462

463

Exposure	Illness consistent with SARS-	ELISA ratio ^a
	CoV-2 ^a	
	POR (95% CI)	exp ^b (95% CI)
Indoor-only	1.63 (0.77, 3.45)	1.07 (0.61, 1.88)
House type ^b	0.52 (0.2, 1.34)	1.79 (1.02, 3.11) (dogs)
		0.51 (0.25, 1.03) (cats)
House square footage	1 (1, 1)	1 (1, 1)
Share bowls ^c	1.29 (0.39, 4.25)	1.78 (1.07, 4.49)
Bedsharing	1.48 (0.66, 3.33)	1.16 (0.68, 1.95)
Took precautions ^d	0.71 (0.29, 1.75)	0.81 (0.48, 1.37)
No. SARS-CoV-2 infected humans	0.78 (0.54, 1.13)	1.18 (0.85, 1.64)
Illness consistent with SARS-CoV-2	-	1.09 (0.59, 2.01)
Time since first exposure (days) ^e	-	1 (1, 1)

464 **Table 2: Regression model results.** House size was adjusted for house type, but no other
465 models were not adjusted for confounders due to overfitting concerns. ^aSurvey results available
466 for 119 dogs and 57 cats, serology results available for 81 dogs and 32 cats. ^bHouse versus
467 apartment or condominium. ^cAnimals and humans share bowls. ^dPrecautions taken to prevent
468 human-animal SARS-CoV-2 transmission following diagnosis: not petting or kissing the animal,
469 staying in a different room, and having someone else feed and walk the animal. ^eFirst exposure
470 defined as 2 days prior to first positive diagnosis in the household or onset of symptoms,
471 whichever was earlier. POR: prevalence odds ratio; 95% CI: 95% confidence interval.

472

473 **Figure 1: Directed acyclic graph for human-animal SARS CoV2 transmission.** Variables
474 outlined with a square are the exposures of interest, while outcome (approximated by serostatus,
475 PCR result, and illness in separate models) is outlined with a circle. HAB: human-animal bond;
476 SES: socioeconomic status; took precautions: SARS-CoV-2 positive household member(s) took
477 precautions to prevent transmission to pet; indoor-only: animal does not go outdoors; bedshare:
478 animal shares a bed with one or more household members.

479 **Figure 2: Flowchart depicting serological and PCR sampling.** Out of 119 dogs and 57 cats
480 corresponding to 105 households with completed surveys, PCR testing is complete for 94 dogs
481 and 39 cats, and serological testing is complete for 81 dogs and 32 cats. The remaining pets were
482 not sampled due to safety concerns.

483 **Figure 3: SARS-CoV-2 RBD ELISA Serology data, cats.** PCR testing is complete for 39 cats,
484 and serological testing is complete for 32 cats. The remaining pets were not sampled due to
485 safety concerns.

486 **Figure 4: SARS-CoV-2 RBD ELISA Serology data, dogs.** PCR testing is complete for 94
487 dogs, and serological testing is complete for 81 dogs. The remaining pets were not sampled due
488 to safety concerns.

489

490

491

492

SES

bioRxiv preprint doi: <https://doi.org/10.1101/2021.04.24.440952>; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license.

Education

Concern about zoonoses

HAB strength

Number of positive household members

House vs. apartment

Indoor only

Share bowls

House ft²

Bedshare

Took precautions

Human-animal transmission





